Geron announces OS data from IMbark in Imetelstat-treated patients with intermediate or high-risk myelofibrosis and r/r to JAK inhibitor

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Geron Corp. announced that results from IMbark, a phase II clinical trial of imetelstat treatment in Intermediate-II or High-risk myelofibrosis patients who are relapsed or refractory to a Janus Kinase inhibitor, were presented at ASH.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login